JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company complete

Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data n

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a

U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26

Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the

SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onco

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onco

Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in app

Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approxi

Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuat

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncol

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lower

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.52) per share which beat the an

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncol

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc

Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-

SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc

Olema Pharmaceuticals (NASDAQ: OLMA - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Ge

SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc

Wolfe Research analyst Kalpit Patel initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) wit

Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 202

Jefferies analyst Dennis Ding assumes Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and l

JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and

Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure

Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lo

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and

Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 sh

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of pala

LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Cont

Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading lower on Monday, in reaction to data from

US stocks fall as Dow Jones drops over 1% on Monday, while NASDAQ and S&P 500 also decline. Korn

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Onc